📰 Eur Thyroid News
Eur Thyroid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eur Thyroid. Real-time updates on events, politics, business and more.
May 21, 2024
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
February 20, 2024
ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company
May 8, 2023
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
May 26, 2022
COSMIC-021 Phase Ib study is evaluating Cabometyx (cabozantinib) in combination with atezolizumab in advanced solid tumors, including non-small cell lung cancer New analyses from pivotal Phase
May 11, 2022
-- Nationwide campaign spotlights mental health impact of living with TED -- For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics plc (Nasdaq: HZNP) is partnering
May 3, 2022
Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 This milestone
May 3, 2022
Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx® (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1This milestone marks the first treatment option to be specifically approved as a second-line therapy in this indicationDisclaimer: Intende...
May 3, 2022
Ipsen announces European Commission approval of the use of Cabometyx® (cabozantinib) as a monotherapy for the treatment of adult patients
March 25, 2022
Recommendation based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 Disclaimer:
May 11, 2021
Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results 1 Detailed results will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Participation in the collaboration will provide Ipsen with access to full trial data to support potential future regulatory submissions Disclaimer: Intended for international media and investor audiences only Regulatory News: Ip...